Correa et al. demonstrated that intranasal delivery of a monoclonal antibody against Nogo-A promoted axonal rewiring and significantly improved neurobehavioral outcomes at chronic stages of stroke (6 weeks) [81]. Here, RTN4 is linked to stroke disorder.